Navigation Links
New Anti-Clotting Drug May Work Better After Hip Replacement
Date:12/23/2010

By Jenifer Goodwin
HealthDay Reporter

WEDNESDAY, Dec. 22 (HealthDay News) -- A new drug, apixaban, may be better for preventing dangerous blood clots in the legs and lungs after hip replacement surgery than a commonly used older drug, a new study finds.

Researchers in Denmark compared the two anti-clotting drugs in a head-to-head test involving about 5,400 hip replacement patients.

About 3.9 percent of patients given the older drug, enoxaparin, developed venous thromboembolism (clot in the legs), a pulmonary embolism (clot in the lungs) or died after the surgery, according to the study.

That compares to only 1.4 percent of patients given apixaban.

Apixaban is being developed by Bristol-Myers Squibb and Pfizer, which funded the Phase III trial reported in the Dec. 23 issue of the New England Journal of Medicine.

The company has applied to the U.S. Food and Drug Administration for drug approval and expects to complete the application process in the first quarter of 2011, said Christina Trank, associate director of public affairs for Bristol-Myers Squibb, headquartered in New York City.

Sanofi-Aventis makes the older drug, enoxaparin (Lovenox).

"The apixaban was superior to enoxaparin, including the total number of patients with thromboembolism and major embolism," said lead study author Dr. Michael Rud Lassen, a spine surgeon and clinical researcher at Horsholm Hospital at the University of Copenhagen.

Deep vein thrombosis is one of the most common complications after lower extremity surgery, including hip and knee replacement, explained Dr. Richard Stein, a professor of cardiology at New York University School of Medicine and a spokesman for the American Heart Association.

Clots can form in the veins of the legs, leading to chronic swelling, and a piece of the clot can break off and travel to the lungs, forming a pulmonary embolism, which can be fatal.

After hip replacement, patients typically receive (warfarin) Coumadin, a blood thinner that inhibits clotting. But Coumadin takes a day or more to kick in, so patients usually are immediately put on enoxaparin, Stein added.

There are several drawbacks to that strategy. Enoxaparin is delivered by injection, whereas apixaban can be taken in oral form.

Coumadin can be somewhat unpredictable and patients taking it have to be monitored, Stein said.

"It often is difficult to find the right dosage. Sometimes we overshoot and patients are at risk of bleeding, and sometimes we undershoot and they are at risk of getting the clot in their vein," Stein said.

The new drug seemed to reduce clots by nearly half and resulted in slightly fewer problems with bleeding at the surgical site, Stein said.

"This is an important article," Stein said. "They showed a reduction in bleeding and a reduction in major and minor complications, including deep vein thrombosis, non-fatal pulmonary embolism or cardiac death, which usually means fatal pulmonary embolism. They showed those risks were reduced substantially in the group taking the apixaban compared to the enoxaparin group."

Apixaban is also being studied for use after knee replacement surgery and for patients with atrial fibrillation, among other conditions. In addition to the hip replacement study, there are eight other completed or ongoing Phase III clinical trials involving the drug, Trank said.

Apixaban is one of several drugs under development that work by inhibiting factor Xa in the blood, according to an accompanying editorial that predicts a huge impact if the drug is "conscientiously priced."

Bristol-Myers Squibb declined to provide information about the cost of the drug.

More information

The U.S. National Heart, Lung, and Blood Institute has more on deep vein thrombosis.

SOURCES: Michael Rud Lassen, M.D., spine surgeon and clinical researcher, Horsholm Hospital, University of Copenhagen, Copenhagen, Denmark; Richard Stein, M.D., professor of cardiology, New York University School of Medicine, New York City; Christina Trank, associate director, public affairs, Bristol-Myers Squibb, New York City; Dec. 23, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Extended use of anti-clotting drug helps some bedridden patients
2. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
3. Memo to Men: To Live Longer, Take Better Care of Your Body
4. Do Breast-Fed Baby Boys Grow Into Better Students?
5. Rash Due to Lung Cancer Drug May Be Linked to Better Survival
6. PSA test better predicts cancer in men taking prostate-shrinking drug
7. New survey device gets better information on teenage sexual behavior
8. Buprenorphine is better than methadone for opioid dependence in pregnant women, study shows
9. UTHealth study suggests private insurers control health care spending better than Medicare
10. Good grades in high school lead to better health, study finds
11. Cognitively-impaired human research subjects need better protection
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Anti-Clotting Drug May Work Better After Hip Replacement
(Date:2/5/2016)... ... , ... The event is being held on April 7, 2016 from 5:30 ... Over Parkinson’s will fund nearly $100,000 for research for the care and cure of ... and is the architect of this informative event to raise awareness and funds for ...
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the ... Carman transitioned to chief of the Division of Plastic Surgery at what is now ... and began a second three-year term in January of 2016. , The original selection ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: each ... longer to access the treadmills. It’s a predictable trend. After the excesses of November ... get in shape by joining gyms, starting new walking or running routines, or signing ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Dr. Justin Scott ... their 2nd Annual No Cost Dental Day to individuals in need. The event is ... of this No Cost Dental Day is to provide dental care to community members ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... year.  Reported sales decreased 3% as currency reduced sales ... earnings per diluted share as reported (EPS) were $4.44, ... EPS was $4.65, an increase of 10% over the ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
Breaking Medicine Technology: